Knowing a patient’s biomarker profile can open up new targeted treatment options for them1–3

High quality next-generation sequencing (NGS) helps you see beyond the tumour origin to exactly which mutations are driving that cancer.4

What’s changing5,6

From primarily looking at the disease origin in the body

To understanding what drives a disease at the molecular level

From one-size fits all medicines

To treatment decisions fitted to a patient's unique disease profile

Targeted therapies are being studied to advance treatment options for patients with actionable biomarkers7,8

  • Biomarkers such as ALK, BRAF, EGFR, HER2, KIT and ROS1 have changed the course of therapy in multiple cancer types9–11
  • NTRK gene fusions are emerging as actionable biomarkers and oncogenic drivers 7,8,12

Research is ongoing to identify novel biomarkers and targeted therapies – such as for NTRK

  • Head and neck cancers
  • Thoracic cancers
  • Breast cancers
  • Gastrointestinal cancers
  • Skin cancers
  • Central nervous system cancers
  • Thyroid cancers 
  • Sarcomas
  • Blood cancers 
  • Genitourinary cancers

High quality NGS can help patients benefit from the latest targeted therapies1,9,25,26

  • Comprehensive Genomic Profiling (CGP) utilises next-generation sequencing technology to broadly analyse the cancer genome and identify all clinically relevant alterations, potentially expanding patients’ treatment options4,26-30
  • NTRK and ROS1 gene fusions can be accurately detected with Comprehensive Genomic Profiling (CGP)4,26-30

Precision medicine combines different treatment options, including traditional cancer therapies and emerging targeted therapies, with the aim of achieving the best possible outcome for the patient5

Footnotes:

CNS, central nervous system; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer.

1

Rozenblum AB, et al. J Thorac Oncol 2017;12:258–268.

2

Schwaederle M, Kurzrock R. Oncoscience 2015;2:779–780.

3

Mansinho A, et al. Expert Rev Anticancer Ther 2017;17:563–565.

4

Frampton GM, et al. Nat Biotechnol 2013;31:1023–1031.

5

Bode AM, Dong Z. npj Precision Onc 2018;2:1.

6

Roche.com. What is Personalised Healthcare all about?

Available from: https://www.roche.com/about/priorities/personalised_healthcare/what_is_phc.htm (Accessed April 2019).

7

Vaishnavi A, Le AT, Doebele RC. Cancer Discov 2015;5:25–34.

8

Amatu A, Sartore-Bianchi A, Siena S. ESMO Open 2016;1:e000023.

9

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
Non-Small Cell Lung Cancer. V.3.2019, 2019.

Available at: www.nccn.org/professionals/physician_gls/recently_updated.aspx (Accessed April 2019).

10

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. V.1.2019, 2019. Available at: www.nccn.org/professionals/physician_gls/recently_updated.aspx (Accessed April 2019).

11

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Acute Myeloid Leukemia. V.2.2019, 2019.

Available at: www.nccn.org/professionals/physician_gls/recently_updated.aspx (Accessed April 2019).

12

Lange AM, Lo HW. Cancers (Basel) 2018;10.

13

Baumgart M, Pandya K. Exp Rev Precis Med Drug Dev 2016;1:25–36.

14

Leonetti A, et al. Cancer Treat Rev 2018;66:82–94.

15

European Society for Medical Oncology. BRAF in Colorectal Cancer: ESMO Biomarker Factsheet.

Available at: https://oncologypro.esmo.org/Education-Library/Factsheets-on-Biomarkers/BRAF-in-Colorectal-Cancer (Accessed April 2019).

16

Dearden S, et al. Ann Oncol 2013;24:2371–2376.

17

Tsao S, et al. J Thorac Oncol 2016;11:613–638.

18

European Society for Medical Oncology. HER2 in Breast Cancer: ESMO Biomarker Factsheet.

Available at: https://oncologypro.esmo.org/Education-Library/Factsheets-on-Biomarkers/HER2-in-Breast-Cancer (Accessed April 2019).

19

Sakabe T, et al. Oncol Lett 2017;13:3703–3708.

20

Bergethon K, et al. J Clin Oncol 2012;30:863–870.

21

Dugay F, et al. Oncotarget 2017;8:53336–53351.

22

Davies K, Doebele RC. Clin Cancer Res 2013;19:4040–4045.

23

Lin J, Shaw A. J Thorac Oncol 2017;12:1611–1625. 

24

Okamura R, et al. JCO Precis Oncol 2018;2018. 

25

Gagan J, Van Allen EM. Genome Med 2015;7:80.

26

Suh JH, et al. Oncologist 2016;21:684–691.

27

Drilon A, et al. Clin Cancer Res 2015;21:3631–3639.

28

Rankin A, et al. Oncologist 2016;21:1306–1314.

29

Ross JS, et al. Cancer 2016;122:2654–2662.

30

Hirshfield KM, et al. Oncologist 2016;21:1315–1325.